PIRS — Pieris Pharmaceuticals Balance Sheet
0.000.00%
- $9.57m
- -$9.51m
- $42.81m
- 28
- 88
- 20
- 42
Annual balance sheet for Pieris Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 104 | 70.4 | 118 | 59.2 | 26.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.79 | 1.71 | 3.31 | 5.81 | 6.04 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 115 | 75.7 | 128 | 73.4 | 38.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 22.9 | 26 | 23 | 20.7 | 0 |
Other Long Term Assets | |||||
Total Assets | 141 | 105 | 154 | 95.5 | 38.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 27 | 22.1 | 50.6 | 36.6 | 11.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 89.7 | 74 | 103 | 67.6 | 11.9 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 51.4 | 31 | 50.8 | 27.9 | 26.8 |
Total Liabilities & Shareholders' Equity | 141 | 105 | 154 | 95.5 | 38.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |